chartexchange

RPRX
Royalty Pharma plc Class A
stockNASDAQ

At CloseNov 18, 2026 3:59:59 PM EST
68.68USD0.000%(0.00)3,192,451
After-hoursNov 18, 2026 4:16:30 PM EST
69.65USD+1.410%(+0.97)
Loading…
Loading…
Healthcare
Biotechnology
HQ
New York, NY, USA
Previous Close
$68.68
Beta
0.24
52-Week High
$70.37 2026-11-12
52-Week Low
$37.31 2025-11-24
SMA 50
$61.77
SMA 200
$54.89
Avg. Vol 10D
3.68M
Avg. Vol 30D
3.38M
Avg. Vol 90D
3.08M
Relative Vol
0.99
445.27M
417.14M
13,075,722
0.2800%
5,900,000
Nov 13, 2026 · $0.235
Oct 15, 2010 · 1-for-4 (reverse)
RPRX Profile

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma's strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott's humira®, j&j/merck's remi

RPRX Performance
PeriodPriceDateChangeBeta
1W70.012026-11-11-1.89%0.341
1M60.272026-10-19+13.97%0.225
3M59.692026-08-18+15.08%0.176
6M52.072026-05-18+31.92%-0.051
1Y39.462025-11-18+74.08%0.245
2Y25.802024-11-18+166.24%—
5Y41.982021-11-18+63.63%0.425
RPRX Stock Summary

Royalty Pharma plc Class A (NASDAQ:RPRX) stock price today is $68.69, and today's volume is 3,361,574. RPRX is up 0.015% today. The 30 day average volume is 3.38M. RPRX market cap is $30.59B with 445.27M shares outstanding.